Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 14/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20393309 | 0.94 | EPHX1 (0.46) | KDM1AEPHX1 | |
| SCHEMBL19167980 | 0.79 | KDM1A (0.39) | KDM1A | |
| SCHEMBL20647592 | 0.79 | KDM1A (0.36) | KDM1A | |
| SCHEMBL12344215 | 0.77 | KDM1A (0.69) | KDM1AACHEEPHX1GRIN2DGRIN3B | |
| SCHEMBL14907186 | 0.75 | ACHE (0.41) | ACHEEPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL23419736 | 0.74 | KDM1A (0.35) | KDM1A | |
| SCHEMBL21473433 | 0.74 | KDM1A (0.35) | KDM1A | |
| SCHEMBL19174298 | 0.74 | KDM1A (0.35) | KDM1A | |
| SCHEMBL14907251 | 0.73 | GRIN2D (0.57) | ACHEEPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL23373220 | 0.73 | KDM1A (0.35) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044728-A1 | PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-3736261-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3350157-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2022-01-05 | — | — | EP | disclosed |
| WO-2021026358-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2021-02-11 | — | — | WO | disclosed |
| EP-3736261-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2020061367-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20170233332-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-17 | — | — | US | disclosed |
| US-20170224844-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-10 | — | — | US | disclosed |
| US-20170210697-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-27 | — | — | US | disclosed |
| US-20170210698-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-27 | — | — | US | disclosed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210697-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | KDM1A 4726/4885ACHE 4857/4885EPHX1 3059/4885 |
| US-20170233332-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | KDM1A 4726/4885ACHE 4857/4885EPHX1 3059/4885 |
| US-20170210698-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | KDM1A 4726/4885ACHE 4857/4885EPHX1 3059/4885 |
| US-20170224844-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | KDM1A 4726/4885ACHE 4857/4885EPHX1 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.